Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

unprecedented number of orphan receptors, and our addiction and high-risk bleeding programs advanced toward the clinic. Following the close of the quarter, we added over $17 million to our balance sheet, positioning Omeros to execute on a series of value-driving milestones during the remainder of 2013 and well into 2014."

Third Quarter and Recent Highlights

  • Reported U.S. and European regulators had accepted Omeros' OMS302 marketing applications for review. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery® product designed to maintain intraoperative mydriasis, prevent miosis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery. Omeros is preparing for a planned commercial launch of OMS302 in the second half of 2014.
  • Announced that Omeros entered into a settlement agreement with Carolina Casualty Insurance Company, or, CCIC, dated October 2, 2013, related to CCIC's defense of, and coverage obligations owed to, Omeros and its chief executive officer and chairman, Dr. Demopulos, in previously settled litigation with Omeros' former chief financial officer. The settlement included a release of each party's respective claims in the insurance coverage lawsuit and payment by CCIC of $12.5 million to Omeros, which was received on October 24, 2013.
  • Reported positive clinical data from its Phase 1 clinical program evaluating OMS824, the lead compound from its phosphodiesterase 10 (PDE10) program. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia.  Omeros subsequently started a Phase 2 trial evaluating the drug in patients with schizophrenia and plans to start a Phase 2 trial in Huntington's disease in early 2014. OMS824 has received orphan drug designation from the
    '/>"/>

  • SOURCE Omeros Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
    2. Omeros to Present at the 12th Annual Needham Healthcare Conference
    3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
    4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
    5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
    6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
    7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
    8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
    9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
    10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
    11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2014)... 2014 2014 Market Research ... professional and in-depth research report on the ... information, including Polyacrylamide definition, classification, application, and ... overview. This research covers the international market ... global industry analysis covering macroeconomic environment & ...
    (Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
    (Date:8/29/2014)... Three Lawrence Livermore researchers have ... Production R&D Award for their research in ... sunlight. , Shared with collaborators from the National ... Nevada, Las Vegas (UNLV), the award recognizes the ... solar-hydrogen production and corrosion processes. , These models ...
    (Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., a ... food processing industry, is asking industry professionals to prepare ... of the E2 soap they’re currently using to the ... . Hand hygiene is critical to fighting cross-contamination ... environment. Six key criteria are identified to evaluate the ...
    Breaking Biology Technology:International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Livermore Team Awarded for Hydrogen Production Research 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
    ... - Third Quarter 2007 Financial Results and Business Update - ... - Thursday, November 15, 11:30 a.m. Eastern Time -, ... , TSX: WHT), a developer of mechanical circulatory,support systems, will ... of the results and a business update in a,teleconference at ...
    ... experts have,abandoned the over 100 year old tuberculin ... assays such as QuantiFERON(R)-TB Gold (QFT(TM)),for screening patients ... (such as anti-TNF-a therapy). In recommendations,published in the ... the use of QFT(TM) in place of the ...
    ... and TORONTO, Nov. 13 /PRNewswire/ - BioRelix, ... based therapeutic agents and,Dalton Medicinal Chemistry, have ... therapeutics. Dalton Medicinal Chemistry will utilize ... novel classes of compounds against selected,RiboSwitch targets. ...
    Cached Biology Technology:Swiss Experts Recommend QuantiFERON(R)-TB Gold for Tuberculosis Infection Screening Prior to Initiating anti-TNF-a Therapy 2Swiss Experts Recommend QuantiFERON(R)-TB Gold for Tuberculosis Infection Screening Prior to Initiating anti-TNF-a Therapy 3BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology 2
    (Date:8/31/2014)... past several decades, malaria diagnosis has changed very little. After ... the blood across a glass slide, stains it with a ... parasite, which causes the disease. This approach gives an accurate ... an important measure of disease severity but is not ... research team from the Singapore-MIT Alliance for Research and Technology ...
    (Date:8/29/2014)... (Aug. 29, 2014) Scientists at the Barshop Institute ... of Medicine at the UT Health Science Center at ... the tissues of the longest-lived rodent, the naked mole ... the cells of naked mole rats protects and alters ... damaged and obsolete proteins. , The factor also protects ...
    (Date:8/29/2014)... how the repeated climatic shifts over the last ... genetic diversity, a team of researchers led by ... Carnaval developed a new biodiversity metric called "phylogeographic ... the genetic variation within species is restricted in ... of biology, and 14 other researchers from institutions ...
    Breaking Biology News(10 mins):A new way to diagnose malaria 2A new way to diagnose malaria 3Factor in naked mole rat's cells enhances protein integrity 2CCNY team defines new biodiversity metric 2
    ... complex societies, researchers are sequencing the genomes of social insects. ... Edition of Proceedings of the National Academy of Sciences ... harvester ant, Pogonomyrmex barbatus . A team, lead ... Gadau, sequenced one of the genomes and set out to ...
    ... ON New research from the University of Toronto could ... who suffer from obstructive sleep apnea. In a recent ... scientists from the University demonstrated that repeated obstruction of the ... of this chemical helps the brain learn to breathe more ...
    ... 2011 A scientist from The Scripps Research Institute has identified ... blood clot formation. The molecule could become a target for ... diseases such as Hemophilia A. The findings, from a ... published in a recent edition of Journal of Biological ...
    Cached Biology News:Seeking social genes 2Scripps Research scientist discovers natural molecule indirectly prevents stable clot formation 2Scripps Research scientist discovers natural molecule indirectly prevents stable clot formation 3
    ... causing shortages in your laboratory or fellow researchers ... distractions, problems and delays. • ... endeavour! Bring us your idea and let us ... work under ISO 9001 quality assurance in design, ...
    ...
    ... Topoisomerase I from vaccinia virus is a ... positive and negative superhelical turns (also called ... DNA. The product of the reaction is ... positive or negative superhelical turns. DNA Topoisomerase ...
    Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
    Biology Products: